Clinical Trials Directory

Trials / Completed

CompletedNCT03492333

Gluten Free Diet in IBS Patients Stratified According to Their Antigliadin Status

The Role of Antigliadin Antibodies in Predicting the Beneficial Effect of Gluten Free Diet in Unselected IBS Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
75 (actual)
Sponsor
McMaster University · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

Gluten-free diet has been shown to improve gut symptoms in patients with celiac disease and also in adult patients with diagnosis of Irritable Bowel Syndrome (Rome III criteria). Antibodies to native gliadin (AGA) have been suggested as a potential diagnostic marker of response to GFD. However, this has not been tested in a prospective study in IBS patients. Identification of predictors of a symptomatic response to GFD within the IBS population would improve the clinical management of these patients. The purpose of this study is to evaluate the effect of gluten-free diet on gastrointestinal symptoms and gut motility in patients with Irritable Bowel Syndrome stratified according to their antigliadin antibodies status. Additional purposes include investigating effects gluten free diet may have on other parameters: * Improvement of mood * Quality of life and general well-being * Changes in gut microbiota

Conditions

Interventions

TypeNameDescription
OTHERGluten free dietGluten-free diet- Instructions provided by a dietitian

Timeline

Start date
2012-04-30
Primary completion
2016-05-30
Completion
2016-05-30
First posted
2018-04-10
Last updated
2018-04-10

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03492333. Inclusion in this directory is not an endorsement.